There are 396 resources available
146P - Impact of heart, lung and oesophageal doses on overall survival (OS) of small cell lung cancer (SCLC) patients following radical chemo-radiotherapy (RT)
Presenter: Bilal Tahir
Session: Poster Display session
57P - Acquired concurrent EGFR T790M and driver gene resistance from EGFR-TKIs hampered osimertinib efficacy in advanced lung adenocarcinoma
Presenter: Fang Wu
Session: Poster Display session
58P - A predictive model of the diagnostic value of next generation sequencing based genomics testing in patients with metastatic non-small cell lung cancer in Spain
Presenter: Alba Mota
Session: Poster Display session
59P - Clinical utility of plasma cell-free DNA EGFR mutation analysis in treatment-naïve stage IV non-small cell lung cancer patients
Presenter: Bo-Guen Kim
Session: Poster Display session
167P - KRAS G12C lung adenocarcinoma represents a distinct group of patients with different response to immunotherapy
Presenter: Laura Pinto
Session: Poster Display session
168P - Characterization of the lung tumor microenvironment upon anti-PD-L1 therapy reveals an ambiguous role for TNF-α
Presenter: Kirsten De Ridder
Session: Poster Display session
152P - Immunotherapy for extensive-stage SCLC: Uncovering clinical gaps in physician knowledge and practice
Presenter: Victoria Harvey-Jones
Session: Poster Display session
153P - Safety profile and associated costs of therapies for relapsed small cell lung cancer in Switzerland
Presenter: Markus Joerger
Session: Poster Display session
18P - RATIONALE-307: Safety analysis of patients (pts) receiving tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone in advanced squamous (sq) NSCLC
Presenter: Xinmin Yu
Session: Poster Display session
19P - Stable disease (SD) on amivantamab in post-platinum epidermal growth factor receptor (EGFR) Exon 20 insertion (Exon20ins) mutated non-small cell lung cancer (NSCLC): A response-based analysis
Presenter: Nicolas Girard
Session: Poster Display session